

UCSF

UC San Francisco Previously Published Works

Title

Acute Stroke Imaging Research Roadmap III Imaging Selection and Outcomes in Acute Stroke Reperfusion Clinical Trials: Consensus Recommendations and Further Research Priorities.

Permalink

<https://escholarship.org/uc/item/35z2g8wb>

Journal

Stroke, 47(5)

Authors

Warach, Steven

Luby, Marie

Albers, Gregory

et al.

Publication Date

2016-05-01

DOI

10.1161/STROKEAHA.115.012364

Peer reviewed



HHS Public Access

Author manuscript

Stroke. Author manuscript; available in PMC 2018 July 25.

Published in final edited form as:

Stroke. 2016 May ; 47(5): 1389–1398. doi:10.1161/STROKEAHA.115.012364.

Acute Stroke Imaging Research Roadmap III:

Imaging Selection and Outcomes in Acute Stroke Reperfusion Clinical Trials: Consensus Recommendations and Further Research Priorities

Steven J. Warach, MD PhD,

Department of Neurology, Dell Medical School, University of Texas at Austin, Austin, TX, USA

Marie Luby, PhD,

National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH), Bethesda, MD, USA

Gregory W. Albers, MD,

Department of Neurology, Stanford University School of Medicine, Stanford, CA, USA

Roland Bammer, PhD,

Department of Radiology, Stanford University School of Medicine, Stanford, CA, USA

Andrew Bivard, MD PhD,

Department of Neurology, John Hunter Hospital, Hunter Medical Research Institute, University of Newcastle, Australia

Bruce C.V. Campbell, MD PhD,

Departments of Medicine and Neurology, Melbourne Brain Centre at the Royal Melbourne Hospital, University of Melbourne, Parkville, Victoria, Australia

Colin Derdeyn, MD,

Department of Radiology, University of Iowa Hospitals and Clinics, Iowa City, IA, USA

Jeremy J. Heit, MD PhD,

Department of Radiology, Neuroradiology Section, Stanford University School of Medicine, Stanford, CA, USA

Pooja Khatri, MD,

Department of Neurology, University of Cincinnati, Cincinnati, OH, USA

Maarten G. Lansberg, MD PhD,

Department of Neurology, Stanford University School of Medicine, Stanford, CA, USA

David S. Liebeskind, MD,

Address for correspondence and reprint requests: Max Wintermark, M.D., Professor of Radiology and (by courtesy) Neurology, Neurological Surgery, Psychiatry and Behavioral Sciences, Chief of Neuroradiology, Stanford University, Department of Radiology, Neuroradiology Division, 300 Pasteur Drive, Room S047, Stanford, CA 94305-5105, Office Phone: (650) 736-6172, Max.Wintermark@gmail.com.

Disclosures

Marie Luby – none
Andrew Bivard - none
Jeremy J. Heit – none
Jean-Claude Baron – none
Josep Puig – none

Neurovascular Imaging Research Core and UCLA Stroke Center, Department of Neurology, University of California, Los Angeles, CA, USA

Charles B.L.M. Majoie, MD,
Department of Radiology, AMC, Amsterdam, The Netherlands

Michael P. Marks, MD,
Department of Radiology, Neuroradiology Section, Stanford University School of Medicine, Stanford, CA, USA

Bijoy K. Menon, MD MSc,
Calgary Stroke Program, Departments of Clinical Neurosciences and Radiology, Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada

Keith W. Muir, MD,
Institute of Neurosciences & Psychology, University of Glasgow, Southern General Hospital, Glasgow, Scotland, UK

Mark W. Parsons, MD PhD,
Department of Neurology, John Hunter Hospital, Hunter Medical Research Institute, University of Newcastle, Australia

Achala Vagal, MD,
Department of Neuroradiology, University of Cincinnati, Cincinnati, OH, USA

Albert J. Yoo, MD,
Texas Stroke Institute, Plano, TX, USA

Andrei V. Alexandrov, MD,
Department of Neurology, The University of Tennessee Health Science Center, Memphis, TN, USA

Jean-Claude Baron, MD ScD,
INSERM U894, Centre Hospitalier Sainte-Anne, Sorbonne Paris Cité, Paris, France, and
Department of Clinical Neurosciences, University of Cambridge, UK

David J. Fiorella, MD PhD,
Department of Neurosurgery, State University of New York at Stony Brook, Stony Brook, NY, USA

Anthony J. Furlan, MD,
Department of Neurology, University Hospitals Case Medical Center and Case Western Reserve University, Cleveland, OH, USA

Josep Puig, MD,
Department of Radiology, Hospital Josep Trueta, Girona, Spain

Peter D. Schellinger, MD PhD, and
Department of Neurology and Geriatrics, Johannes Wesling Klinikum Minden, Minden, Germany

Max Wintermark, MD MAS
Department of Radiology, Neuroradiology Section, Stanford University School of Medicine, Stanford, CA, USA

Abstract

Background and Purpose—The STroke Imaging Research (STIR) group, the Imaging Working Group of StrokeNet, the American Society of Neuroradiology and the Foundation of the American Society of Neuroradiology sponsored an imaging session and workshop during the Stroke Treatment Academy Industry Roundtable (STAIR) IX on October 5–6, 2015 in Washington, D.C. The purpose of this roadmap was to focus on the role of imaging in future research and clinical trials.

Methods—This forum brought together stroke neurologists, neuroradiologists, neuroimaging research scientists, members of the National Institute of Neurological Disorders and Stroke (NINDS), industry representatives, and members of the U.S. Food and Drug Administration (FDA) to discuss stroke imaging research priorities in the light of an unprecedented series of positive acute stroke endovascular therapy clinical trials.

Results—The imaging session summarized and compared the imaging components of the recent positive endovascular trials, and proposed opportunities for pooled analyses. The imaging workshop developed consensus recommendations for optimal imaging methods for the acquisition and analysis of core, mismatch and collaterals across multiple modalities, and also a standardized approach for measuring the final infarct volume in prospective clinical trials.

Conclusions—Recent positive acute stroke endovascular clinical trials have demonstrated the added value of neurovascular imaging. The optimal imaging profile for endovascular treatment includes large vessel occlusion, smaller core, good collaterals and large penumbra. However, equivalent definitions for the imaging profile parameters across modalities are needed, and a standardization effort is warranted, potentially leveraging the pooled data resulting from the recent positive endovascular trials.

Keywords

imaging; image-guided intervention; reperfusion; clinical trial; outcome Subject codes; Ischemic Stroke; Computerized Tomography (CT); Imaging; Magnetic Resonance Imaging (MRI); Treatment

Introduction

Over the prior two decades, an accumulated body of evidence from the stroke research community has led to incremental advances in the standardization of clinical trial methodologies and to the emergence of a central role for imaging in new treatment evaluations. The recent series of positive endovascular trials owe much of their success to the lessons learned from the many prior trials that failed to establish therapeutic efficacy.^{1–5} These prior stroke trials have led to an understanding of the roles of vascular, core, penumbral, and collateral imaging and their relationships to treatment response and clinical outcome. The goal of this article is to report on neuroimaging biomarkers for treatment selection and for outcome.

It is beyond question that time from onset of focal cerebral ischemia to reperfusion is fundamental in determining therapeutic efficacy for reperfusion therapies.⁶ The effect of

early treatment of stroke with intravenous alteplase demonstrated in the hallmark NINDS trial⁷ illustrates this principle; a robust and reliable benefit compared to placebo is related to time from onset to treatment.⁸

However, when time and brain imaging by standard non-contrast CT (NCCT) imaging are insufficient to accurately test a therapeutic hypothesis, selection based on imaging of a biological target for treatment is a logical alternative (Table 1). Examples may be clinical trials in which the anticipated effect size is small (e.g., comparing two thrombolytic medications or testing of a neuroprotective drug) or in which the treatment is relevant only for a subset of stroke types (e.g., large vessel occlusion). The STIR consortium has recommended the term TRAIT (Treatment-Related Acute Imaging Target) to describe patient selection based upon the biologic target of a treatment. The responses of these biologic targets to treatment may depend on time.⁹ The series of positive endovascular trials confirmed the value of TRAIT selection and enrichment for endovascular reperfusion strategies (Table 1). The trials demonstrated that patient recruitment limited to an imaging defined subset of stroke led to positive trials with smaller samples completed within reasonable periods of time. EXTEND IA illustrates how a greater enrichment results into a smaller sample and greater effect size, but potentially also decreased generalizability and excluded patients who may have benefited from treatment.

Imaging Selection in Recent Positive Acute Stroke Endovascular Clinical Trials

After three neutral endovascular trials in 2013 (IMS III, MR RESCUE and SYNTHESIS)^{10–13}, the years 2014–2015 were marked by a historic series of positive acute stroke clinical trials (Table 2). The use of advanced imaging-based selection for patient recruitment in these recent trials is one of the most important factors in the success of these trials (Table 3). The imaging modalities required for each trial were different (Table 4). There is no evidence that the different imaging modalities resulted in different times from symptom onset to treatment (Table 5).

In the MR CLEAN trial¹, the key imaging findings included a clear benefit of endovascular therapy for NCCT ASPECTS scores of 5–10, but less certainty for ASPECTS score of 0–4. A post-hoc analysis demonstrated that a good and moderate collateral score was also associated with a large benefit of endovascular therapy. On the other hand, while Perfusion CT (PCT) mismatch (CBV and MTT thresholds) predicted functional outcome, the relative treatment effect in patients with and without mismatch was similar. The use of an ischemic core volume >70mL on PCT criterion did identify a group of patients with very low rates of independent outcome (1/13 (8%) endovascular treated patients achieved mRS 0–2) but there were relatively few patients and the interaction test was not significant.¹⁴

The EXTEND IA trial² showed a robust effect of endovascular therapy over alteplase alone in patients with PCT-defined mismatch and core volume <70mL. In this group of patients, near complete reperfusion (>90%) in target mismatch patients was strongly tied to favorable clinical outcome (regardless of the treatment strategy) and lack of reperfusion was associated with death or dependence in 70% of patients.

In the ESCAPE trial³, an imaging strategy of NCCT ASPECTS scores of 6–10, as well as good and moderate collateral scores on CT Angiography (CTA), showed a robust effect favoring endovascular therapy. ASPECTS and collateral scores were highly correlated. Patients with higher clot burden assessed using the clot burden score demonstrated more treatment effect.

In the SWIFT PRIME trial⁴, a target mismatch based on perfusion imaging combined with successful recanalization was associated with a favorable outcome. Final infarct volume strongly correlated with clinical outcome in both treatment groups.¹⁵ Baseline ischemic core volume predicted 27-hour infarct volume in patients who reperfused.¹⁶ In target mismatch patients, the combination of baseline core and 27-hour hypoperfusion volume predicted final infarct volume.

The REVASCAT trial⁵ supported NCCT-based patient selection, only requiring ASPECTS of 6 or greater, demonstrating a robust treatment effect. However, significant discrepancies were observed between the centralized core lab ASPECTS and the investigators' ASPECTS, and some benefit with lower ASPECTS scores (0–4) cannot be excluded. A pooled analysis of all patients with ASPECTS 0–4 across all endovascular trials is needed, but may be too small to draw reliable conclusions regarding endovascular treatment effects. Interestingly, there were also significant discrepancies between M1 versus M2 occlusions between the core lab and the investigators. It is important to note that, if the inclusion criteria were expanded to fully embrace the actual recruited subjects (e.g. lower ASPECTS to 3–10 range) that a similar cohort would be enrolled and still show benefit.

THERAPY ([ClinicalTrials.gov](https://clinicaltrials.gov/ct2/show/study/NCT01429350) Identifier: NCT01429350), which required hyperdense clot length measurement ≥ 8 mm on NCCT for trial inclusion, suggested that the benefit of bridging endovascular therapy relative to IV thrombolysis alone increased with hyperdense clot length, and large infarcts as measured by final NCCT ASPECTS 0–4 to be associated with very poor outcome providing further support for this threshold as a useful treatment exclusion criterion.

The THRACE study ([ClinicalTrials.gov](https://clinicaltrials.gov/ct2/show/study/NCT01062698) Identifier: NCT01062698) has not been published to date. This study required demonstration of an arterial occlusion but similar to MR CLEAN, did not utilize NCCT or other criteria to exclude patients with a large ischemic core.

Opportunities for Standardization

While the above listed stroke clinical trials had several elements in common (occlusion location, ischemic core size), they also had significant differences, which represents a unique opportunity for standardization. More specifically, the scoring systems used to characterize ischemic core and collateral circulation varied from trial to trial. The pooling of the imaging data from these trials offers great opportunities to refine the imaging selection of patients for acute reperfusion therapy and trials (last column in Table 4). A statistical analysis plan for the pooled analysis of all the endovascular trials have been published¹⁷, which will focus on ASPECTS, M1 versus other arterial occlusion sites, and good/moderate versus poor collaterals. The optimal set of imaging biomarkers to select acute stroke patients may vary

depending on the revascularization therapy being considered, the population being studied, and the time window under investigation, in agreement with the concept of TRAITs defined in STIR Roadmap II¹⁸. Imaging remains essential for phase II trials, and more than one imaging method is probably acceptable for patient selection purposes, as long as reasonable cross-modality concordance and within modality standardization and reliability are achieved. The STAIR/STIR imaging workshop recommends imaging based selection for acute stroke reperfusion clinical trials (not limited to endovascular therapies) as outlined in Table 1.

The specific imaging methods proposed for patient selection using each TRAIT are outlined in Table 1. Table 1 contains the acceptable options for patient selection in clinical trials and are not listed in any order of priority.

Exclusion of patients with large *ischemic core* was a feature of most of the recent positive acute stroke clinical trials. Since the interaction of treatment with this imaging variable cannot be determined reliably due to the very small numbers of subjects across all trials, neither safety nor efficacy of reperfusion therapies in this group is established. Future studies investigating the sensitivity and specificity of each method/modality used to define ischemic core is essential.^{16,19} Furthermore, studies investigating the relationship between the ischemic core volume and collaterals²⁰ should be pursued. The definitions of ischemic core will need to be revisited in populations of patients with ultra-fast reperfusion. The geographic distribution of the ischemic core may need to be considered in addition to its volume to reflect the eloquence of the infarcted region. Finally, future studies will need to determine whether treatment of patients with larger ischemic cores is associated with higher rates of symptomatic intracranial hemorrhage when treated. The research priorities for core and the other TRAITs are outlined in Table 6.

Standardization of the grading of *collateral circulation* on and between CT and MRI are needed. The importance of collateral circulation must also be more robustly validated in prospective acute ischemic stroke. Future studies comparing single-phase and multiphase CTA²¹ for this purpose, are warranted, considering that a dichotomous definition of collaterals (absent/poor versus good/moderate) is probably sufficient.

Perfusion derived entities, such as the *core* and *penumbra*, are the imaging biomarkers that will require the largest effort in terms of standardization considering the number of existing definitions and the differences between imaging modalities. Core is defined generally as the irreversible ischemic area that is injured beyond therapy benefit. Penumbra is defined generally as the at risk hypoperfused area surrounding the core that is the target for therapy to be salvaged. There are now data sets available to benchmark and compare processing of acute PCT against a concurrent DWI scan.¹⁹ Also, much of the previous work to define optimal thresholding did not involve patients with ultra early reperfusion, and repeat work should be undertaken using the imaging data collected in these patients.

These efforts to refine and standardize imaging selection must also inform the concept of *futility* in stroke reperfusion therapy. A futile imaging profile should identify groups of patients in whom a therapy offers little to no clinical benefit particularly if an increased risk

of harm is greater than any predicted benefit. A futile profile will depend on a number of considerations, including time from onset window, anatomic location of existing core infarction, type of treatment, and other clinical variables, such as patient age, NIHSS score, and patient preferences.²² One commonly used definition of unfavourable outcome, mRS 3–6, ignores potentially meaningful shifts from severe to moderate disability. The dichotomous approach has been modified to classify mRS 4–6 as poor clinical outcome (e.g. hemicraniectomy for space occupying cerebral edema). However an ordinal analysis approach using the full scale of the mRS to generate numbers needed to treat (NNT) to achieve an improvement of at least 1 level on the mRS (perhaps combining 5 and 6 if that transition is not deemed meaningful) is an alternative approach that avoids arbitrary dichotomies. Similarly, patient-oriented outcomes, such as the NeuroQol or PROMIS, may also be considered. Recent small studies have shown that they correlate well with the mRS but have greater capacity to discriminate smaller but still meaningful change.^{23,24} In order to address the issue of futility, future research efforts should use pooled analysis of data from recent trials as well as large imaging based observational studies that enroll either patients without the TRAITs or all comers with a subsequent analysis of outcome by imaging profile to derive futility thresholds for current reperfusion therapy.²⁵

Two ongoing trials, PRACTISE ([ClinicalTrials.gov](https://clinicaltrials.gov/ct2/show/study/NCT02360670) Identifier: NCT02360670) and PISTE-2, have been designed to better understand imaging selection strategy and the impact on treatment, rather than to test a specific treatment. PRACTISE is currently testing CT-based advanced imaging selection in IV thrombolysis decisions. PISTE-2 will have two arms, one with advanced imaging and one without advanced imaging selection and it is hoped that these will provide information on the added value of advanced imaging.

Final infarct volume

Final infarct volume (FIV) can potentially be a useful biomarker in phase II trials to provide an early signal of efficacy for a new treatment. The rationale is that FIV is a more direct measurement of biological effect of acute treatment compared to clinical outcome at 90 days or later which may depend heavily on infarct location and can be affected by unrelated pathology. However, it is not clear that FIV is an equivalent or more powerful measure of treatment effect than clinical measures of outcome. This is an important research question that has been addressed in earlier treatment trials of t-PA (imaging outcomes less powerful than clinical outcome measures to detect treatment effect with t-PA) but has yet to be investigated in the current endovascular trials. What is clear is that all FIV imaging approaches are known to correlate with long-term clinical outcome. However, what matters is not the degree of correlation but rather the ability to properly classify patients to predict accurately the long-term outcome.

The best approach and timing for measuring FIV requires further investigation. Measuring FIV early after stroke treatment (within 24 to 48 hours) has the advantage that the majority of patients remain in hospital, but the disadvantages that the lesion volume and signal intensity may still be changing or may be confounded by edema and by parenchymal hematomas. Early mortality at this time point is uncommon and becomes increasingly problematic with later imaging endpoints as it inevitably leads to missing data in a biased

manner. Measuring FIV later (30–90 days) has the advantage of a more stable true final lesion, but the patient is less likely to be available for follow-up scan, tissue atrophy may underestimate the infarct volume, and distinguishing the index infarct from chronic ischemic damage may be impossible, or at least subjective. At all time points lesion detection and contrast is superior for MRI than CT, making it the preferred modality for final lesion volume measurement.

However, CT may be required when MRI is contraindicated or unavailable. The recommended MRI sequence to determine the FIV is diffusion-weighted imaging (DWI) at 24–48 hours.²⁶ Performing DWI earlier than 24 hours risks underestimating lesion volume due to temporary post-reperfusion reversal.²⁷ MRI with FLAIR imaging performed at 3–5 days or just before discharge is an alternative approach that reduces the potential risk of late infarct growth occurring in non-reperfused patients whilst minimizing loss to follow-up.²⁸ However, differentiating the acute lesion from chronic ischemia can be more challenging and edema is prominent at this time. The optimal timing for CT follow up (when MRI is not available) needs further investigation (i.e., 24–72 hours versus 3–5 days). Research on confounding factors including edema, hemorrhagic transformation, contrast staining on CT, fogging, etc. are necessary to increase validity of the use of final infarct volume as a biomarker. Adjustment to account for the anatomical location and distribution of the final infarct relevant to clinical outcome whether it affects eloquent regions or not, would clearly be relevant to models aiming to predict functional outcome. However, for assessment of biological treatment effect, removal of this potential confound may be a benefit rather than a pitfall.

The research priorities for final infarct volume are outlined in Table 6.

Imaging Technology Issues

Imaging selection for acute stroke could benefit from several technological improvements that would ensure that the requirement for speed does not result in reduced use of advanced imaging which could impair future pathophysiologic insights and treatment advances.

MRI use could become more widespread with recent advances in rapid stroke imaging protocols but would require an effective fast safety screening process. The risk associated with the administration of gadolinium needs to be addressed, and alternative approaches to assess perfusion such as arterial spin labeling need to be further evaluated.

NCCT could benefit from a focus on improving image acquisition quality and workflow that would improve core detection, including characterization of ASPECTS score. A focus on standardizing optimal acquisition techniques, and the biophysics of image reconstruction algorithms, would be helpful, and should consider a wide range of CT technologies available, including the emerging availability of CT-equipped mobile stroke ambulances.

PCT would benefit greatly from increased signal contrast to noise through improved software and perhaps contrast agent approaches. Faster image reconstruction, transfer and processing are critical, not just to produce standardized maps but to rapidly generate dynamic angiography. Minimum hardware requirements such as ability to operate at low

kilovoltage of 80 kV (or 70kV when available), volumetric coverage, and safety dose-check features should be considered.

Rapid technological advances could open new horizons in terms of imaging selection of acute stroke patients for treatment.

Conclusion

Recent positive acute stroke endovascular clinical trials have demonstrated the added value of neurovascular imaging. The optimal imaging profile for endovascular treatment includes large vessel occlusion, smaller core, good collaterals and large penumbra. However, equivalent definitions for the imaging profile parameters across modalities are needed, and a standardization effort is warranted, potentially leveraging the pooled data resulting from the recent positive endovascular trials.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Sources of Funding

This manuscript, and the efforts that led to it, were supported by the Stroke Imaging Research (STIR) group, by Virtual International Stroke Trials Archive (VISTA), by the American Society of Neuroradiology (ASNR) and the Foundation of the American Society of Neuroradiology, as well as by generous donations from General Electric Healthcare, Siemens Healthcare, Bayer and Toshiba Medical Systems. Additional sources of funding included: Roland Bammer - NIH RO1 EB002711, Colin Derdeyn - NIH NS086872, David S. Liebeskind - NIH-NINDS grant: K24NS072272 and Max Wintermark - GE-NFL advisory board for TBI.

Steven J. Warach - Research support from Siemens Healthcare, Genentech, NINDS

Gregory W. Albers - Consultant: iSchemaView and Medtronic (both significant), Equity interest: iSchemaView (significant)

Roland Bammer - Co-Founder and shareholder of iSchemaView, Inc., NIH RO1 EB002711

Bruce C. V. Campbell - reports research support from the National Health and Medical Research Council of Australia (GNT1043242, GNT1035688), Royal Australasian College of Physicians, Royal Melbourne Hospital Foundation, National Heart Foundation, National Stroke Foundation of Australia and unrestricted grant funding for the EXTEND-IA trial to the Florey Institute of Neuroscience and Mental Health from Covidien (Medtronic).

Colin Derdeyn - Pulse Therapeutics – stock options, mechanical adjunct to IV tPA for stroke, NIH NS086872, Penumbra – honorarium – DSMB for 3D separator trial (acute stroke treatment device) Microvention – contract with Washington University – Angio Core Lab for LVIS trial (brain aneurysms), Pulsar Vascular – contract with Washington University – Angio Core Lab for ANSWERS trial (brain aneurysms)

Pooja Khatri - The University of Cincinnati Dept of Neurology receives funds for her research efforts from Genentech (PRISMS Lead PI), THERAPY (THERAPY Neurology Lead PI), and Biogen (DSMB member). She received travel funds for workshop participation from Neuravi. She receives fees for consultation (medicolegal, Grand Rounds Experts-online clinical consultation) and royalties (UpToDate-online publication).

Maarten G. Lansberg – NIH grant (PI for Stanford)

David S. Liebeskind - NIH-NINDS grant: K24NS072272

Charles B.L.M. Majoie - PI MRCLEAN, Stryker: payment for lectures to institution

Michael P. Marks - NIH grant (PI for Stanford)

Bijoy K. Menon - Reports membership of the Steering and Executive Committee, ESCAPE trial that received support from Covidien Inc., Site Principal Investigator, SOCRATES Trial, sponsored by Astra Zeneca, honoraria from Penumbra Inc., a provisional patent 62/086077 for triaging systems in ischemic stroke, research funding from CIHR, HSFC, AIHS, HBI and the Faculty of Medicine, University of Calgary and board membership of QuikFlo Health Inc.

Keith W. Muir - PRACTISE trial is funded by the National Institute of Health Research (UK); PISTE-2 (PISTE-AI) is subject of an application for funding, also to NIHR, collaborative projects with Toshiba Medical Visualisation Systems

Mark W. Parsons - Australian National Heart Foundation Research Fellowship

Achala Vagal - Received CTSA 8 UL1 TR000077-05 KL2 Grant and grant support from Genentech, Inc for Imaging Core Laboratory of Study of the Efficacy and Safety of Alteplase in Patients With Mild Stroke (PRISMS) Trial

Albert J. Yoo - Penumbra Inc., modest research grant from Neuravi Inc.

Andrei V. Alexandrov - Speaker Bureau, Genentech and Boehringer Ingelheim; Consultant, Siemens; Honorary Advisor to the Board and Director, Neurosonology Examination, American Society of Neuroimaging

David J. Fiorella - Consultant: Medtronic, Codman/JnJ, Microvention, Penumbra Inc, Sequent Medical Research Support: Siemens Medical Imaging, Penumbra Inc, Sequent Medical, Microvention

Anthony J. Furlan - Consultant Medtronic (no direct compensation)

Peter D. Schellinger - Boehringer Ingelheim

Max Wintermark - GE-NFL advisory board for TBI

We thank Gary Houser for his invaluable efforts in organizing and facilitating the STAIR conference.

Appendix

Significant Contributors

*Sameer A. Ansari, MD PhD – Departments of Radiology, Neurology, and Neurological Surgery, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA

*Richard I. Aviv, MRCP, FRCR (UK), FRCP (C), DABR, Department of Medical Imaging, University of Toronto and Sunnybrook Health Science Centre, Toronto, Canada

* Andrew D. Barreto, MD – Department of Neurology, University of Texas Health Science Center at Houston, Houston, TX, USA

*Joseph P. Broderick, MD – Department of Neurology, University of Cincinnati Neuroscience Institute, Cincinnati, OH, USA

*Søren Christensen, PhD – Stanford University School of Medicine, Stanford, CA, USA

*Stephen M. Davis, MD – The Royal Melbourne Hospital, University of Melbourne, Parkville, Victoria, Australia

*Andrew M. Demchuk, MD – Departments of Clinical Neurosciences and Radiology, Hotchkiss Brain Institute, University of Calgary; Calgary, AB Canada

- *Diederik W. Dippel, MD - Erasmus MC University Medical Center, Rotterdam, The Netherlands
- *Geoffrey A. Donnan, MD – The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Victoria, Australia
- *Jochen B. Fiebach, MD – Academic Neuroradiology, Center for Stroke Research Berlin, Charité - Universitätsmedizin Berlin, Germany
- *Jens Fiehler, MD – Department of Diagnostic and Interventional Neuroradiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
- *Gary Houser – The Stroke Group, Centennial, CO, USA
- *James C. Grotta, MD – Department of Neurology, Memorial Hermann Hospital - TMC, Houston, TX, USA
- *Werner Hacke, MD PhD – Department of Neurology, University of Heidelberg, Heidelberg, Germany
- *Michael D. Hill, MD – Departments of Clinical Neurosciences, Radiology Medicine, Community Health Sciences, Hotchkiss Brain Institute, University of Calgary; Calgary, AB Canada
- *Amie W. Hsia, MD – National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH), Bethesda, MD, USA
- *Tudor G. Jovin, MD – Department of Neurology, University of Pittsburgh Medical Center, Stroke Institute and UPMC Center for Neuroendovascular Therapy, Pittsburgh, PA, USA
- *Martin Köhrmann, MD – Department of Neurology, Universitätsklinik Erlangen, Erlangen, Germany
- *Lawrence L. Latour, PhD – National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH), Bethesda, MD, USA
- *Kennedy R. Lees, MD – Institute of Cardiovascular & Medical Sciences, University of Glasgow, Glasgow, UK
- *Richard Leigh, MD – National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH), Bethesda, MD, USA
- *Michael D. Lev, MD – Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
- *Randolph S. Marshall, MD MS – Department of Neurology, Columbia Presbyterian Medical Center, New York, NY, USA
- *J Mocco, MD – Department of Neurosurgery, Mount Sinai Health System, New York, NY, USA

- *Zurab Nadareishvili, MD PhD – National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH), Bethesda, MD, USA
- *Raul G. Nogueira, MD – Neuroendovascular Service, Marcus Stroke & Neuroscience Center, Grady Memorial Hospital, Emory University School of Medicine, Atlanta, GA, USA
- * Jean Marc Olivot, MD – Department of Neurology, UMR 825, CHU de Toulouse, Université Toulouse III – Paul Sabatier, Toulouse, France
- *Yuko Palesch, PhD - Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC, USA
- *Salvador Pedraza, MD – Servicio de Radiología, Hospital Josep Trueta, Girona, Spain
- *Makoto Sasaki, MD PhD – Division of Ultrahigh Field MRI, Institute for Biomedical Sciences, Iwate Medical University, Yahaba, Japan
- *Jeffrey L. Saver, MD – Department of Neurology, Geffen School of Medicine at UCLA, Los Angeles, CA, USA
- *Sean I. Savitz, MD - Department of Neurology, University of Texas Medical School at Houston, Houston, Texas, USA
- *Lee H. Schwamm, MD - Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
- *Alexis Simpkins, MD – National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH), Bethesda, MD, USA
- *Wade S. Smith, MD PhD – Department of Neurology, University of California, San Francisco, San Francisco, CA, USA
- *Vincent Thijs, MD – Department of Neurology, Austin Health and Melbourne Brain Center, Florey Institute of Neuroscience and Mental Health, Heidelberg, Victoria, Australia
- *Götz Thomalla, MD PhD – Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
- *Lawrence R. Wechsler, MD - Department of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
- *Ona Wu, PhD – Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
- *Greg Zaharchuk, MD PhD – Department of Radiology, Stanford University School of Medicine, Stanford, CA, USA
- *Osama O. Zaidat, MD – Department of Neurology, Medical College of Wisconsin and Froedtert Hospital, Milwaukee, WI, USA

References

1. Berkhemer OA, Majoie CB, Dippel DW, Investigators MC. Endovascular therapy for ischemic stroke. *N Engl J Med.* 2015; 372:23632.
2. Campbell BC, Mitchell PJ, Kleinig TJ, Dewey HM, Churilov L, Yassi N, et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection. *N Engl J Med.* 2015; 372:1009–1018. [PubMed: 25671797]
3. Goyal M, Demchuk AM, Menon BK, Eesa M, Rempel JL, Thornton J, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke. *N Engl J Med.* 2015; 372:1019–1030. [PubMed: 25671798]
4. Saver JL, Goyal M, Bonafe A, Diener HC, Levy EI, Pereira VM, et al. Stent-retriever thrombectomy after intravenous t-pa vs. T-pa alone in stroke. *N Engl J Med.* 2015; 372:2285–2295. [PubMed: 25882376]
5. Jovin TG, Chamorro A, Cobo E, de Miquel MA, Molina CA, Rovira A, et al. Thrombectomy within 8 hours after symptom onset in ischemic stroke. *N Engl J Med.* 2015; 372:2296–2306. [PubMed: 25882510]
6. Eilaghi A, Brooks J, d'Esterre C, Zhang L, Swartz RH, Lee TY, et al. Reperfusion is a stronger predictor of good clinical outcome than recanalization in ischemic stroke. *Radiology.* 2013; 269:240–248. [PubMed: 23716707]
7. The national institute of neurological disorders and stroke rt-pa stroke study group. Tissue plasminogen activator for acute ischemic stroke. *N Engl J Med.* 1995; 333:1581–1587. [PubMed: 7477192]
8. Emberson J, Lees KR, Lyden P, Blackwell L, Albers G, Bluhmki E, et al. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: A meta-analysis of individual patient data from randomised trials. *Lancet.* 2014; 384:1929–1935. [PubMed: 25106063]
9. Kemmling A, Flottmann F, Forkert ND, Minnerup J, Heindel W, Thomalla G, et al. Multivariate dynamic prediction of ischemic infarction and tissue salvage as a function of time and degree of recanalization. *J Cereb Blood Flow Metab.* 2015; 35:1397–1405. [PubMed: 26154867]
10. Kidwell CS, Jahan R, Alger JR, Schaewe TJ, Guzy J, Starkman S, et al. Design and rationale of the mechanical retrieval and recanalization of stroke clots using embolectomy (mr rescue) trial. *Int J Stroke.* 2014; 9:110–116. [PubMed: 22974139]
11. Hill MD, Demchuk AM, Goyal M, Jovin TG, Foster LD, Tomsick TA, et al. Alberta stroke program early computed tomography score to select patients for endovascular treatment: Interventional management of stroke (ims)-iii trial. *Stroke.* 2014; 45:444–449. [PubMed: 24335227]
12. Ciccone A, Valvassori L, Nichelatti M, Sgoifo A, Ponzio M, Sterzi R, et al. Endovascular treatment for acute ischemic stroke. *N Engl J Med.* 2013; 368:904–913. [PubMed: 23387822]
13. Broderick JP, Palesch YY, Demchuk AM, Yeatts SD, Khatri P, Hill MD, et al. Endovascular therapy after intravenous t-pa versus t-pa alone for stroke. *N Engl J Med.* 2013; 368:893–903. [PubMed: 23390923]
14. Borst J, Berkhemer OA, Roos YB, van Bavel E, van Zwam WH, van Oostenbrugge RJ, et al. Value of computed tomographic perfusion-based patient selection for intra-arterial acute ischemic stroke treatment. *Stroke.* 2015 [Accessed February 10, 2016] [published online ahead of print November 5, 2015]. <http://stroke.ahajournals.org/content/early/2015/11/05/STROKEAHA.115.010564>.
15. Albers GW, Goyal M, Jahan R, Bonafe A, Diener HC, Levy EI, et al. Relationships between imaging assessments and outcomes in solitaire with the intention for thrombectomy as primary endovascular treatment for acute ischemic stroke. *Stroke.* 2015; 46:2786–2794. [PubMed: 26316344]
16. Albers GW, Goyal M, Jahan R, Bonafe A, Diener HC, Levy EI, et al. Ischemic core and hypoperfusion volumes predict infarct size in swift prime. *Ann Neurol.* 2015 [Accessed February 10, 2016] [published online ahead of print December 12, 2015]. <http://onlinelibrary.wiley.com/doi/10.1002/ana.24543/abstract;jsessionid=1EC8E4E91DAF6BB02A3C719665FD8D49.f04t01>.

17. MacIsaac RL, Khatri P, Bendszus M, Bracard S, Broderick J, Campbell B, et al. A collaborative sequential meta-analysis of individual patient data from randomized trials of endovascular therapy and tPA vs. tPA alone for acute ischemic stroke: Thrombectomy And tPA (TREAT) analysis: statistical analysis plan for a sequential meta-analysis performed within the VISTA-Endovascular collaboration. *Int J Stroke*. 2015 [Accessed February 10, 2016] [published online ahead of print September 9, 2015]. <http://wso.sagepub.com/content/10/SA100/136.long>.
18. Wintermark M, Albers GW, Broderick JP, Demchuk AM, Fiebach JB, Fiehler J, et al. Acute stroke imaging research roadmap ii. *Stroke*. 2013; 44:2628–2639. [PubMed: 23860298]
19. Cereda CW, Christensen S, Campbell BCV, Mishra NK, Mlynash M, Levi C, et al. A benchmarking tool to evaluate computer tomography perfusion infarct core predictions against a DWI standard. *J Cereb Blood Flow Metab*. 2015 [Accessed February 10, 2016] [published online ahead of print October 19, 2015]. <http://jcb.sagepub.com/content/early/2015/10/19/0271678X15610586.long>.
20. Fanou EM, Knight J, Aviv RI, Hojjat SP, Symons SP, Zhang L, et al. Effect of collaterals on clinical presentation, baseline imaging, complications, and outcome in acute stroke. *AJNR Am J Neuroradiol*. 2015 [Accessed February 10, 2016] [published online ahead of print October 15, 2015]. <http://www.ajnr.org/content/36/12/2285.long>.
21. Menon BK, d'Este CD, Qazi EM, Almekhlafi M, Hahn L, Demchuk AM, et al. Multiphase ct angiography: a new tool for the imaging triage of patients with acute ischemic stroke. *Radiology*. 2015; 275:510–520. [PubMed: 25633505]
22. Murphy A, Symons SP, Hopyan J, Aviv RI. Factors influencing clinically meaningful recanalization after iv-rtpa in acute ischemic stroke. *AJNR Am J Neuroradiol*. 2013; 34:146–152. [PubMed: 22700751]
23. Naidech AM, Beaumont JL, Berman M, Francis B, Liotta E, Maas MB, et al. Dichotomous "good outcome" indicates mobility more than cognitive or social quality of life. *Crit Care Med*. 2015; 43:1654–1659. [PubMed: 25978337]
24. Naidech AM, Beaumont JL, Berman M, Liotta E, Maas MB, Prabhakaran S, et al. Web-based assessment of outcomes after subarachnoid and intracerebral hemorrhage: a new patient centered option for outcomes assessment. *Neurocrit Care*. 2015; 23:22–27. [PubMed: 25510897]
25. Eilaghi A, d'Este CD, Lee TY, Jakobovic R, Brooks J, Liu RT, et al. Toward patient-tailored perfusion thresholds for prediction of stroke outcome. *AJNR Am J Neuroradiol*. 2014; 35:472–477. [PubMed: 24113471]
26. Campbell BC, Tu HT, Christensen S, Desmond PM, Levi CR, Bladin CF, et al. Assessing response to stroke thrombolysis: validation of 24-hour multimodal magnetic resonance imaging. *Arch Neurol*. 2012; 69:46–50. [PubMed: 21911654]
27. Campbell BC, Purushotham A, Christensen S, Desmond PM, Naqakane Y, Parsons MW, et al. The infarct core is well represented by the acute diffusion lesion: sustained reversal is infrequent. *J Cereb Blood Flow Metab*. 2012; 32:50–6.26. [PubMed: 21772309]
28. Tourdias T, Renou P, Sibon I, Asselineau J, Bracoud L, Dumoulin M, et al. Final cerebral infarct volume is predictable by mr imaging at 1 week. *AJNR Am J Neuroradiol*. 2011; 32:352–358. [PubMed: 20966063]

Table 1

Imaging recommendations for methods and patient selection for clinical reperfusion trials

Baseline imaging markers that favor treatment response of thrombectomy	
Treatment-Related Acute Imaging Target (TRAIT) for thrombectomy	
<ul style="list-style-type: none"> • Large artery occlusion • Small core • Large core-perfusion mismatch (penumbral marker) • Good cerebral collaterals 	
Imaging selection of patients for acute reperfusion trials (not limited to endovascular therapies): Recommendations	
<ul style="list-style-type: none"> • Imaging for defining the Treatment Relevant Acute Imaging Target (TRAIT) is highly recommended for patient selection • Additional time spent acquiring additional imaging information must be balanced against risk of delay in initiating reperfusion therapies • Pre-randomization vascular imaging should be obtained in acute endovascular trials. This would usually be done by CTA or MRA. Catheter angiography is included as a method for patient selection but it is understood that it is not likely the initial method for patient selection in a clinical trial • Vascular, core, mismatch and collateral imaging each have added value for identifying TRAIT and enriching sample toward greatest effect size. More than one imaging method and threshold criterion is acceptable for these purposes, but should be standardized within a trial • Particularly in phase II trials with small sample sizes, both vascular and advanced tissue imaging may offer insights into patient populations that cannot be obtained from clinical data alone, and are recommended to assist characterization of patient populations and improve understanding of experimental therapies 	
Proposed imaging methods for patient selection	
TRAIT	Proposed imaging methods
Artery occlusion	<ul style="list-style-type: none"> • CTA • MRA • Catheter angiography
Core	<ul style="list-style-type: none"> • ASPECTS on NCCT • Volume of severely decreased CBV or CBF from PCT • Volume of acute DWI lesion from MRI
Mismatch	<ul style="list-style-type: none"> • Volume of perfusion lesion (by PCT, Magnetic Resonance Perfusion (MRP) or Arterial Spin Labeling (ASL)) to core volume
Cerebral collaterals	<ul style="list-style-type: none"> • CTA source images • Single- or multiphase CTA • Contrast-enhanced MRA • Catheter angiography

Table 2

Imaging characteristics in medical treatment and endovascular treatment groups of recent positive acute stroke clinical trials

	MR CLEAN		EXTEND-IA		ESCAPE		SWIFT PRIME		REVASCAT		THERAPY	
	Medical treatment (n=267)	Endovascular treatment (n=233)	Medical treatment (n=35)	Endovascular treatment (n=35)	Medical treatment (n=150)	Endovascular treatment (n=165)	Medical treatment (n=98)	Endovascular treatment (n=98)	Medical Treatment (n=103)	Endovascular Treatment (n=103)	Medical treatment (n=53)	Endovascular treatment (n=55)
Site of vessel occlusion												
ICA	80/266 (30%)	61/233 (26.1%)	11/35 (31.4%)	11/35 (31.4%)	42/150 (28%)	48/165 (29.1%)	15/94 (16%)	17/93 (18.3%)	41/103 (39.8%)	45/103 (43.7%)	12/53 (22.6%)	18/55 (32.7%)
M1	165/266 (62%)	154/233 (66.1%)	18/35 (51.4%)	20/35 (57.2%)	103/150 (68.7%)	111/165 (67.3%)	72/94 (76.6%)	62/93 (66.7%)	65/103 (63.1%)	66/103 (64.1%)	36/53 (67.9%)	31/55 (56.4%)
M2	21/266 (8%)	18/233 (7.8%)	6/35 (17.2%)	4/35 (11.4%)	5/150 (3.3%)	6/165 (3.6%)	6/94 (6.4%)	13/93 (14%)	8/103 (7.8%)	10/103 (9.7%)	5/53 (9.4%)	6/55 (10.9%)
ASPECTS												
Mean±SD	8.4±2.0	8.3±1.8	9.1±1.0	9.2±0.9	8.7±1.4	8.6±1.4	8.5±1.4	8.4±1.5	7.2±2.1	7.4±2.0	7.4±1.7	7.1±2.1
Median (IQR)	9 (8–10)	9 (7–10)	9 (9–10)	9 (9–10)	8 (7–9)	9 (8–9)	9 (8–10)	9 (7–10)	8 (6–9)	7 (6–9)	8 (7–9)	7.5 (6–9)
Ischemic core volume - mL												
Mean±SD	46±44	42±33	20±17	19±19	n/a	n/a	11±11	11±16	n/a	n/a	n/a	n/a
Median (IQR)	32 (10–69)	36 (15–60)	18 (4–29)	12 (4–32)	n/a	n/a	9.0 (1–17)	6.5 (0–14)	n/a	n/a	n/a	n/a
Perfusion volume - mL												
Mean±SD	112±103	141±97	116±48	105±39	n/a	n/a	126±63	116±61	7.2±2.1	n/a	n/a	n/a
Median (IQR)	97 (41–181)	113 (60–190)	115 (72–158)	106 (76–137)	n/a	n/a	133 (79–162)	125 (66–149)	8 (6–9)	n/a	n/a	n/a
Clot length -mm												
Mean±SD	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	15.7±8.7	17.3±11.5
Median (IQR)	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	14.1 (10.1–18.6)	12.9 (9.4–22.2)

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

	MR CLEAN		EXTEND-IA		ESCAPE		SWIFT PRIME		REVASCAT		THERAPY	
	Medical treatment (n=267)	Endovascular treatment (n=233)	Medical treatment (n=35)	Endovascular treatment (n=35)	Medical treatment (n=150)	Endovascular treatment (n=165)	Medical treatment (n=98)	Endovascular treatment (n=98)	Medical Treatment (n=103)	Endovascular Treatment (n=103)	Medical treatment (n=53)	Endovascular treatment (n=55)
Collateral grade 0 (worst)/1/2/3/4 (best) or the ESCAPE trial collateral imaging criteria	9/72/111/71	17/64/88/64	n/a	n/a	145 adequate vs 5 poor	162 adequate vs 3 poor	n/a	n/a	n/a	n/a	7/6/10/1/6/6	7/9/11/1/1/6

Table 3

Imaging selection criteria for recent positive acute stroke clinical trials

<i>Imaging selection criteria</i>	MR CLEAN	EXTEND-IA	ESCAPE	SWIFT PRIME	REVASCAT	THERAPY
<i>Vessel occlusion</i>	ICA, M1, M2, A1, A2 occlusion	ICA, M1, M2	ICA, M1 or functional M1 occlusion (both/all M2 occlusion)	ICA, M1	ICA or M1 occlusion	ICA, M1 or M2 occlusion -Hyperdense clot length ≥ 8 mm -Absence of tandem extracranial steno-occlusive disease requiring treatment prior to thrombectomy
<i>Small core</i>	<i>Not required</i>	RAPID perfusion infarct <70mL (reICBF<30% threshold)	ASPECTS score 6-10	ASPECTS score 6-10 on NCT or DWI, RAPID perfusion infarct <50mL (reICBF<30% threshold)	ASPECTS score >6 on NCCT, ASPECTS score >5 on DWI (NCCT ASPECTS >8 for age 80-85)	Acute ischemic changes on NCCT less than one-third of MCA territory
<i>Penumbra</i>	<i>Not required</i>	Target mismatch: RAPID perfusion ischemic core mismatch ratio>1.2, absolute mismatch >10mL (Tmax>6 sec threshold)	<i>Not required</i>	Target Mismatch: RAPID perfusion penumbra/infarct ratio>1.8, penumbra absolute volume >15mL (Tmax>6 sec threshold) - Tmax>10s lesion 100mL	<i>Not required</i> (Clinical/core mismatch [NIHSS >5])	<i>Not required</i>

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

<i>Imaging selection criteria</i>	MR CLEAN	EXTEND-IA	ESCAPE	SWIFT PRIME	REVASCAT	THERAPY
<i>Collaterals</i>	<i>Not required</i>	<i>Not required</i>	Adequate collateral circulation defined as some filling of 50% or greater of the ischemic territory pial circulation beyond occlusion on CT angiography (preferably multiphase CTA)	<i>Not required</i>	<i>Not required</i>	<i>Not required</i>

Imaging modalities obtained at baseline in trial patients (required imaging indicated with an asterisk*). The last column indicates the total number of imaging studies available for pooling.

Table 4

<i>Modality</i>	MR CLEAN	EXTEND-IA	ESCAPE	SWIFT PRIME	REVASCAT	THERAPY	Total
<i>Noncontrast CT (NCCT)</i>	499/500 (99.8%)*	70/70 (100%)*	313/315 (99.4%)*	163/195 (83.6%)*	206/206 (100%)*	108/108 (100%)*	1,359
<i>Perfusion CT (PCT)</i>	333/500 (66.6%) 175/500 (35%) available	70/70 (100%)*	138/315 (43.8%)*	139/195 (71.2%)*	64/206 (31.1%)*	40/108 (37.0%)*	784
<i>CT Angiography (CTA)</i>	496/500 (99.2%)*	70/70 (100%)*	313/315 (99.4%)*	159/195 (81.5%)*	195/206 (94.7%)*	99/108 (91.7%)*	1,332
<i>Diffusion-Weighted MR Imaging (DWI)</i>	19/500 (3.8%)	none	2/315 (0.006%)	34/195 (17.4%)*	11/206 (5.3%)*	3/108 (2.8%)*	69
<i>Perfusion-Weighted MR Imaging (PWI)</i>	none	none	none	34/195 (17.4%)*	5/206 (2.4%)*	1/108 (0.9%)*	40
<i>MR Angiography (MRA)</i>	2/500 (0.4%)*	none	2/315 (0.006%)	32/195 (16.4%)*	11/206 (5.3%)*	2/108 (1.9%)*	49

Median times (and interquartile range) for imaging and to treatment in recent positive acute stroke clinical trials, in minutes

Table 5

	MR CLEAN	EXTEND-IA	ESCAPE	SWIFT PRIME	REVASCAT	THERAPY
<i>Multimodal CT acquisition time</i>	n/a	6min28s (range: 3min37s-9min0sec)	n/a	8 (4-21)	n/a	n/a
<i>PCT post-processing time</i>	n/a	5min20s (range: 3-10min)	n/a	3.9 (2.2-5.4)	n/a	n/a
<i>Multimodal MR acquisition time</i>	n/a	n/a	n/a	12 (7-15)	n/a	n/a
<i>PWI/DWI post-processing time</i>	n/a	n/a	n/a	2 (1.5-2.7)	n/a	n/a
“Door-to-Arterial Access” time, min						
<i>for entire IA cohort</i>	n/a	109 (78-150)	76 (62-108)	90 (69-120)	109 (85-163)	142 (85-179.5)
<i>for patients selected based on NCCT alone</i>	n/a	n/a	n/a	n/a	n/a	96.5 (83.5-128.5) (n=4)
<i>for patients selected based on NCCT+CTA</i>	n/a	n/a	76 (62-108)	84 (55-102)	108.0 (85-163)	150.5 (121.5-200.5) (n=28)
<i>for patients selected based on NCCT+CTA+PCT</i>	n/a	109 (78-150)	n/a	90 (69-112)	103.0 (76-136)	101 (68-160) (n=18)
<i>for patients selected based on MRI</i>	n/a	n/a	n/a	84 (55-102)	114.0 (94-155)	114.5 (56-173) (n=2)

Table 6

Research priorities

Patient selection research priorities	
Standardization of core, mismatch and collaterals definitions	
<ul style="list-style-type: none"> • Standardizing acceptable methods and imaging parameters within and across modalities • Comparability of NCCT ASPECTS, DWI, PCT volume estimates and thresholds, collateral scores on multi-phase or single-phase CTA • Equivalent definitions and thresholds of mismatch across modalities including coregistration methods between core and perfusion imaging in order to precisely measure the mismatch volume • Acceptable variability, i.e. inter-rater reliability, centralized review versus individual site review • Defining futility thresholds • Validation of semi-automated methods or fully automated methods of image quantification across vendor platforms, devices and modalities 	
Final infarct volume research priorities	
<ul style="list-style-type: none"> • Recommended as outcome measure at Phase II to assess biological effect of therapy • Comparison to baseline core volume preferred (volume of change or statistical adjustment) • Acceptable variability, i.e. inter-rater reliability, centralized review versus individual site review • Optimal timing and modality/sequence • Correction for edema, shift due to mass effect, hemorrhagic transformation, atrophy and pre-existing chronic lesions 	

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript